BioPharmSignal logoBioPharmSignal

Biotech News

Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

Cyclerion (CYCN)CyclerionPartnership

Cyclerion Has Renegotiated Praliciguat License Agreement to Obtain Upfront and Near-Term Payments as well as Entered into a License Option Agreement for Olinciguat CAMBRIDGE, Mass. , Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its

Open original release

Related news

ABOSAcumen Pharmaceuticals2026-06-16 11:30 EST

Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease

OGENOragenics2026-05-07 12:30 EST

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

CYCNCyclerion2026-04-01 11:05 EST

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

AXSMAxsome2026-06-01 11:00 EST

Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month

TEVATeva Pharmaceutical Industries2026-04-29 11:00 EST

Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

AXSMAxsome2026-06-15 11:00 EST

Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026

View all latest news

Cyclerion

Cyclerion was a biotechnology company focused on cyclic nucleotide biology and central nervous system or vascular-related disease programs before becoming a historical ticker. Its story reflected the challenge of turning a mechanistic platform into a durable drug franchise.

Recent company news

CYCNCyclerion2026-04-01 11:05 EST

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

CYCNCyclerion2026-02-17 12:00 EST

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

CYCNCyclerion2026-01-05 21:01 EST

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression

CYCNCyclerion2025-09-23 20:01 EST

Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company

CYCNCyclerion2024-12-17 13:08 EST

Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

Stock data

Close
3.50 USD
Market cap
13.08M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States